All In Biotech

Drug Trial Radar · NCT06347159

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Adults With Hypertrophic Cardiomyopathy

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

79

Planned (sponsor's estimate)

Start

Apr 11, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Conditions

  • Hypertrophic Cardiomyopathy

Interventions

  • EDG-7500Drug

    Liquid suspension formulation of EDG-7500

  • EDG-7500Drug

    Solid oral formulation of EDG-7500

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: From screening through study completion (Part A: Up to 38 days; Part B and C: Up to 73 days; Part D: Up to 18 months)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Stanford University Hospital / Stanford Health Care

    Stanford, California

  • Emory Clinic

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • Michigan Medicine - Michigan Clinical Research Unit

    Ann Arbor, Michigan

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri

  • Morristown Medical Center (Atlantic Health System)

    Morristown, New Jersey

  • North Shore University Hospital

    Manhasset, New York

  • NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only)

    New York, New York

  • Sanger Heart and Vascular Institute

    Charlotte, North Carolina

  • Duke Health Center Arringdon

    Morrisville, North Carolina

  • The Lindner Research Center at Christ Hospital

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Virginia Heart and Vascular Center Fontaine

    Charlottesville, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.